# Unilever Plc To acquire Horlicks and other products from GSK

- Link: https://www.directorstalkinterviews.com/unilever-plc-to-acquire-horlicks-and-other-products-from-gsk/412762407
- Published: 2018-12-03T09:54:48+00:00
- Author: Charlotte Edwards

**[Unilever Plc](https://www.directorstalkinterviews.com/ftse-company/unilever-plc/ulvr.l)**(
[LON:ULVR](https://www.directorstalkinterviews.com/ftse-company/unilever-plc/ulvr.l))
announced today it has signed an agreement to acquire the Health Food Drinks portfolio(
GSK HFD) of [GlaxoSmithKline](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l)(
GSK) in India, Bangladesh and 20 other predominantly Asian markets.

The transaction consists of three elements:

· all-Equity Merger of Hindustan Unilever Ltd (HUL) with the publicly listed GSK
Consumer Healthcare India (GSK CH India),

· acquisition of 82% stake in GSK Bangladesh Limited (GSK Bangladesh), and

· acquisition of certain other commercial operations and assets outside India.

Unilever’s share of the total consideration is €3.3bn payable using a combination
of cash, and shares in its listed subsidiary in India, Hindustan Unilever Limited.

In 2018, the GSK HFD portfolio delivered total turnover of c.€550m, primarily through
the Horlicks and Boost brands. Almost 90% of the turnover is in India.

The transaction is aligned with Unilever’s stated strategy of increasing its presence
in health-food categories and in high-growth emerging markets.

GSK HFD is the undisputed leader in the Health Food Drinks category in India, with
iconic brands such as Horlicks and Boost, and a product portfolio supported by strong
nutritional claims. This portfolio has a long history in India with Horlicks having
originally been introduced in the 1930s. Horlicks products have been an everyday
staple in South Asian households across generations. Over the last 15 years, the
portfolio (and category) has grown at a double-digit rate. Despite this, the category
still remains under-penetrated in India. Unilever is well positioned to further 
develop the market given the extent of its reach and capabilities.

> **Nitin Paranjpe, President, Food & Refreshment, Unilever, said:** “We are delighted
> to be acquiring the GSK Health Food Drinks portfolio. The iconic Horlicks brand
> has a deep heritage, credibility and resonance around the world. The acquisition
> is transformative for our Foods and Refreshment business allowing us to enter 
> the Health Foods Drinks category, further strengthening our position in health
> and wellness. It is rare to be able to acquire brands with such leading market
> positions and fantastic consumer equity in one of the world’s most exciting and
> fast-growing markets. Improving the health and wellbeing of 1 billion people by
> 2020 is a key pillar in our Unilever Sustainable Living Plan. Horlicks and Boost
> will add to our stable of purpose driven brands that help consumers to get more
> out of their lives.”
> **Sanjiv Mehta, Chairman and CEO, Hindustan Unilever said:** “With this strategic
> merger of Hindustan Unilever and GSK Consumer Healthcare India Limited, we will
> be expanding our portfolio through great brands into a new category catering to
> the nutritional needs of our consumers. I am confident that this merger will create
> significant shareholder value through both revenue and cost synergies. The turnover
> of our Foods & Refreshments business will now exceed Rs. 100bn and we will become
> one of the largest F&R businesses in the country. We look forward to welcoming
> new brands and great talent into the Unilever and HUL family, once the transaction
> is complete.”

Transaction and Financial Considerations

As outlined above, the transaction consists of three elements:

**1. All-Equity Merger of HUL with the publicly listed GSK CH India**

The merger of HUL with GSK CH India will be on the basis of an exchange ratio of
4.39 HUL shares for each GSK CH India Share.

This implies a total equity value of INR 317bn (c.€3.96bn) for 100% of GSK CH India
and represents a premium of c.5%, based on the 15-day VWAP of both the respective
shares ending 30th November 2018. Following the issue of new HUL shares, Unilever’s
holding in HUL will be diluted from 67.2% to 61.9%.

The merger includes the totality of operations within GSK CH India, including a 
consignment selling contract to distribute GSK’s Over-the-Counter and Oral Health
products in India.

**2. Acquisition of 82% stake in GSK Bangladesh**

Unilever will acquire, for cash, 82% of the shares of the publicly listed GSK Bangladesh
Limited at an equity value of BDT 16bn (c.€169m), implying an EV/EBITDA multiple
of c.15x.

**3. Acquisition of certain other commercial operations and assets outside India**

Unilever will also acquire the commercial operations in 20 other predominantly Asian
markets and the intellectual property rights for a total consideration of c.€470m
in cash.

The total consideration for the transaction is c.€4.6bn, of which Unilever’s implied
contribution through both cash and through the issue of shares in HUL, its listed
subsidiary in India, totals c.€3.3bn.

Unilever expects to achieve substantial synergies. Cost synergies are expected from
a combination of supply chain efficiencies and operational improvements, go-to-market
and distribution network optimisation, the benefits of scale in a number of cost
areas such as marketing, and streamlining of overlapping infrastructure. The revenue
growth of the HFD portfolio is expected to accelerate through leveraging Unilever’s
vast local distribution and selling capabilities, particularly in India.

Post synergies, the implied EV/EBITDA multiple for the transaction would be below
20x.

By utilising HUL equity to fund the Indian component of the transaction, together
with the synergies outlined above, Unilever shareholders are expected to benefit
from returns well in excess of the cost of capital from Year 4. In addition, the
Transaction will be EPS accretive, on an underlying basis, immediately post completion.

The Transaction is subject to customary regulatory and shareholder approvals, with
expected completion in c.12 months.

Share on:
